![](\"https:\/\/mms.businesswire.com\/media\/20260608624521\/en\/2826055\/5\/Logo_Median.jpg\"){kind=logo}
<\/a><\/a>\nMedian Technologies (Paris:ALMDT):<\/p>
\nPursuant to article L-223-8 II of the French \u201ccode de Commerce\u201d and 223-16 of the AMF\u2019s General Regulations.<\/p>
SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News:<\/p> \nMedian Technologies (Paris:ALMDT):<\/p><\/a><\/a>
\nTotal number of shares<\/p><\/td> | \n38,202,387<\/b><\/p><\/td><\/tr>\n \nNumber of real voting rights* (excluding treasury shares**)<\/p><\/td> \n38,143,292<\/b><\/p><\/td><\/tr>\n \nTheoretical number of voting rights* (including treasury shares**)<\/p><\/td> \n38,179,187<\/b><\/p><\/td><\/tr>\n<\/table> \n(*) Class E preference shares are non-voting\n \nFurthermore, as of May 27, 2026, out of the 14,424,541 warrants (BSA) issued in connection with the 2025 capital increase, 12,325,725 remained outstanding and exercisable.<\/p> \nAbout Median Technologies: <\/strong>Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis\u00ae, an AI\/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit www.mediantechnologies.com<\/a>.<\/p> \nMedian Technologies<\/b> \nInvestors \u2013 SEITOSEI ACTIFIN<\/b> |